Soyasaponin Ab
Based on 1 publication(s) in Google Scholar
Soyasaponin Ab is an orally active soyasaponin. Soyasaponin Ab inhibits PPARγ transcriptional activity. Soyasaponin Ab induces apoptosis in high concentrations. Soyasaponin Ab exerts anti-obesity, anti-oxidation, anti-inflammation, anti-aging effects. Soyasaponin Ab prevents Scopolamine (HY-N0296)-induced memory impairment.
For research use only. We do not sell to patients.
- Purity: 98.23%
- CAS No.: 118194-13-1
- Formula: C67H104O33
- Molecular Weight:1437.52
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Soyasaponin Ab
More
Biological Activity
Soyasaponin Ab (25-100 μM, 8 days ) decreases triglyceride accumulation in a dose-dependent manner in 3T3-L1 adipocytes[1].
Soyasaponin Ab (25-100 μM, 24 h) suppresses the transcriptional activity of peroxisome proliferator-activated receptor γ (PPARγ) in HEK 293T cells[1].
Soyasaponin Ab (50-100 μM, 8 days ) markedly inhibits adipocyte differentiation and expression of various adipogenic marker genes (including adiponectin, ADD1/SREBP1c, aP2, Fas, and resistin) through the downregulation of the adipogenesis-related transcription factors PPARγ and C/EBPα in 3T3-L1 adipocytes[1].
Soyasaponin Ab (1-100 μM, 1 h) shows concentration dependent inhibition of lipid peroxidation in liposomes (IC50 = 14.5 μM)[2].
Soyasaponin Ab (10-50 μM, 48 h) regulates translocation of Nrf2 and protein expressions of the phase II antioxidant enzyme HO-1 and NQO1, through the ERK1/2 signaling pathway in HepG2 cells[2].
Soyasaponin Ab (1-400 μM, 48 h or 10 days) shows little toxicity below 50 μM and reduces the formation of colonies at the dose that above 50 μM and induces apoptosis in HepG2 cells[2].
Soyasaponin Ab (1-10 μM, 16 h or 4 h) significantly reduces Lipopolysaccharides (LPS) (HY-D1056)-stimulated IL-1β, TNF-α and TLR4 expression and PGE2 and NO production in peritoneal macrophages[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 cells
-
Concentration:50, 100, 200, 400 μM
-
Incubation Time:10 days
-
Result:Reduced the formation of colonies in dose-dependent manner, especially in 200 and 400 μM treatment groups.
-
Cell Line:HepG2 cells
-
Concentration:1, 5, 10, 20, 50, 100, 200, 400 μM
-
Incubation Time:48 h
-
Result:The cytotoxicity represented a slight increase after treated with higher concentrations after 48 h, especially for the cells treated over 200 μM. There were some morphological changes including loss of cellular geometry and reduction in proliferation of cells after a 100 μM or more treatment. No obvious change on the cell morphology of the groups treated less than 50 μM.
-
Cell Line:HepG2 cells
-
Concentration:50, 100, 200, 400 μM
-
Incubation Time:48 h
-
Result:Induced some extent of apoptosis in cells in a dose-dependent manner.
-
Cell Line:3T3-L1
-
Concentration:50, 100 μM
-
Incubation Time:8 days
-
Result:Effectively suppressed PPARγ and CEBPα mRNA expression. Markedly reduced expression of various adipogenic marker genes, including adiponectin, ADD1/SREBP1c, aP2, Fas, and resistin.
-
Cell Line:3T3-L1
-
Concentration:50, 100 μM
-
Incubation Time:8 days
-
Result:Significantly suppressed the expression of PPARγ and CEBPα proteins at 50 and 100 μM.
Soyasaponin Ab (5-40 mg/kg; p.o.; one hour before the trial) significantly prevents Scopolamine (HY-N0296)-induced memory impairment in male ICR mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ICR mice (18-22 g, 5 weeks)[4]
-
Dosage:5, 10, 20, 40 mg/kg
-
Administration:Oral gavage (p.o.); One hour before the trial, and memory impairment was induced by intraperitoneal injection of Scopolamine (0.9 mg/kg) 30 min after oral administrations of test agents.
-
Result:Restored memory impairment to 86% at a dose of 10 mg/kg of untreated normal control mice in the passive avoidance task. Restored spontaneous alteration, which was lowered by Scopolamine on the Y-maze task. Significantly shortened the escape latencies on the fifth day.
-
Animal Model:Male institute of cancer research (ICR) mice (20-22 g, 4 weeks)[3]
-
Dosage:10, 20 mg/kg
-
Administration:Oral gavage (p.o.); daily for 5 days
-
Result:Inhibited TNBS-induced body weight reduction, colon shortening, macroscopic score, and myeloperoxidase activity. Inhibited the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Ameliorated changes of TNBS-treated mouse colons which showed increased neutrophils, massive bowel edema, dense infiltration of the superficial layers of the mucosa, and epithelial cell disruption by large ulcerations. Inhibited the expression of TLR4, COX-2, and iNOS and the phosphorylation of IRAK1, IKK-β and p65, although it reversed IRAK-1 expression.
Chemical Information
-
CAS No. 118194-13-1
-
Appearance Solid
-
Molecular Weight 1437.52
-
Formula C67H104O33
-
Color White to off-white
-
SMILES
C[C@]12[C@]3(C([C@@]4([H])[C@](C)([C@@H]([C@H](O)C(C)(C)C4)O[C@@]5([H])[C@@H]([C@H]([C@@H](O)CO5)O[C@@]6([H])[C@@H]([C@H]([C@H](OC(C)=O)[C@@H](COC(C)=O)O6)OC(C)=O)OC(C)=O)O)CC3)=CC[C@]1([H])[C@@]7([C@@]([C@](C)([C@@H](O[C@@]8([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O8)O)O[C@@]9([H])[C@@H]([C@H]([C@@H](O)[C@@H](CO)O9)O)O[C@]%10([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]%10O)CO)CC7)CO)([H])CC2)C)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Foods
Development of Extraction Method for Determination of Saponins in Soybean-Based Yoghurt Alternatives: Effect of Sample pH. [Abstract]2023 May 27;12(11):2164. PMID: 37297409
Solvent & Solubility
DMSO : 100 mg/mL (69.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yang SH, et al. Soyasaponins Aa and Ab exert an anti-obesity effect in 3T3-L1 adipocytes through downregulation of PPARγ. Phytother Res. 2015 Feb;29(2):281-7. [Content Brief]
[3]. Lee IA, et al. Soyasaponin Ab ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages. J Agric Food Chem. 2011 Dec 28;59(24):13165-72. [Content Brief]
[4]. Hong SW, et al. Soyasaponins Ab and Bb prevent scopolamine-induced memory impairment in mice without the inhibition of acetylcholinesterase. J Agric Food Chem. 2014 Mar 5;62(9):2062-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6956 mL | 3.4782 mL | 6.9564 mL | 17.3911 mL |
| 5 mM | 0.1391 mL | 0.6956 mL | 1.3913 mL | 3.4782 mL | |
| 10 mM | 0.0696 mL | 0.3478 mL | 0.6956 mL | 1.7391 mL | |
| 15 mM | 0.0464 mL | 0.2319 mL | 0.4638 mL | 1.1594 mL | |
| 20 mM | 0.0348 mL | 0.1739 mL | 0.3478 mL | 0.8696 mL | |
| 25 mM | 0.0278 mL | 0.1391 mL | 0.2783 mL | 0.6956 mL | |
| 30 mM | 0.0232 mL | 0.1159 mL | 0.2319 mL | 0.5797 mL | |
| 40 mM | 0.0174 mL | 0.0870 mL | 0.1739 mL | 0.4348 mL | |
| 50 mM | 0.0139 mL | 0.0696 mL | 0.1391 mL | 0.3478 mL | |
| 60 mM | 0.0116 mL | 0.0580 mL | 0.1159 mL | 0.2899 mL |